Yahoo · Nov 13, 2026
GSK vs. Zoetis: Which Dividend Stock Pays You More in 10 Years?
Key TakeawaysGSK yields 3. 6% and Zoetis 2.

NASDAQ · ZTS
Healthcare · Drug Manufacturers - Specialty & Generic
$80.79
Down-$4.78 (-5.59%)
Updated Nov 20, 2026, 2:25 AM
SID Score
6.1/10
Composite research score
Smart Money
56/100
Neutral
Price performance · ZTS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
ZTS closed at $80.79 after 21 trading sessions, down 1.48% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $84.84 | $85.13 | $80.71 | $80.79 | 4.71M |
| Nov 18, 2026 | $82.15 | $86.58 | $82.15 | $85.57 | 4.66M |
| Nov 17, 2026 | $84.045 | $85.56 | $83.05 | $83.48 | 3.4M |
| Nov 16, 2026 | $84.26 | $84.57 | $83.175 | $84.39 | 4.09M |
| Nov 13, 2026 | $83.50 | $83.85 | $82.265 | $83.82 | 3.15M |
| Nov 12, 2026 | $82.69 | $83.84 | $82.48 | $82.96 | 4.39M |
| Nov 11, 2026 | $81.49 | $82.64 | $80.79 | $82.57 | 4.45M |
| Nov 10, 2026 | $81.75 | $83.28 | $80.43 | $82.46 | 4.89M |
| Nov 9, 2026 | $80.45 | $82.5987 | $79.59 | $82.32 | 6.21M |
| Nov 6, 2026 | $79.00 | $80.67 | $78.63 | $79.40 | 6.02M |
| Nov 5, 2026 | $84.87 | $88.74 | $81.54 | $82.11 | 10.09M |
| Nov 4, 2026 | $85.37 | $89.29 | $84.83 | $89.20 | 9.18M |
| Nov 3, 2026 | $82.29 | $83.73 | $81.526 | $82.99 | 3.73M |
| Nov 2, 2026 | $80.15 | $83.225 | $79.8901 | $83.18 | 5.42M |
| Oct 30, 2026 | $79.84 | $80.605 | $79.215 | $79.72 | 4.12M |
| Oct 29, 2026 | $78.44 | $79.2805 | $77.76 | $78.80 | 2.94M |
| Oct 28, 2026 | $77.355 | $78.555 | $77.03 | $77.80 | 2.62M |
| Oct 27, 2026 | $80.59 | $80.59 | $78.065 | $78.23 | 2.83M |
| Oct 26, 2026 | $80.95 | $81.19 | $80.10 | $80.97 | 2.9M |
| Oct 23, 2026 | $81.14 | $81.86 | $80.6001 | $81.03 | 2.86M |
| Oct 22, 2026 | $79.90 | $82.29 | $79.90 | $82.00 | 4.83M |
The latest Smart Investors Daily articles mentioning ZTS.
Company
Market Activity
Research & News
ZTS research
Company profile and research snapshot.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | Morgan Stanley | Overweight | — |
| Oct 27, 2026 | UBS | Neutral | — |
| Oct 20, 2026 | Jefferies | Hold | — |
| Oct 16, 2026 | Goldman Sachs | Neutral | — |
| Aug 25, 2026 | TD Cowen | Buy | — |
No generated briefing is available yet.
Yahoo · Nov 13, 2026
Key TakeawaysGSK yields 3. 6% and Zoetis 2.
Yahoo · Nov 11, 2026
PARSIPPANY, N.J., November 11, 2026--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection.
Yahoo · Nov 11, 2026
Despite significantly underperforming the broader market over the past year, Zoetis continues to receive a cautiously optimistic outlook from Wall Street analysts.
Yahoo · Nov 10, 2026
PARSIPPANY, N.J., November 10, 2026--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 2 p.m. GMT.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning ZTS.